The global clinical and commercial partnerships agreed between IQVIA and Veeva Systems include the complete resolution of all pending legal disputes.
The long-term agreement enables customers to use the following offerings from Veeva and IQVIA together – software, data, technology and service.
The global partnerships mean that customers can work with IQVIA and Veeva in these key areas:
Commercial: The companies have established master data and software third-party access (TPA) agreements that allow IQVIA or Veeva data to be used with each other’s software or services in customer instances, including the use of IQVIA data in Veeva Network for master data management (MDM), Veeva Nitro for analytics, and Veeva AI.
In addition to the use of Veeva data in IQVIA’s commercial products and services, IQVIA has also joined the Veeva Technology, AI and Services Partner programmes to support customer integrations between Veeva software and IQVIA Analytics, IQVIA Information Management (including MDM), IQVIA Agentic AI and IQVIA Commercial Orchestration offerings.
Clinical: IQVIA has joined Veeva’s CRO Clinical Data Partner programme and can leverage the Veeva Clinical Suite to execute clinical trials using Veeva software products, including study builds with Veeva EDC.
“We are committed to supporting frictionless product and services integration with IQVIA for the benefit of our joint customers and the industry overall,” said Peter Gassner, Veeva founder and CEO.
He continued: “I am excited about the potential for our clinical and commercial partnerships to create significant value for our shared customers.”
Ari Bousbib, chairman and CEO of IQVIA, said: “This will enable IQVIA customers on Veeva platforms to accelerate clinical development, bring treatments to market more efficiently and improve access to innovations for patients.”